Search Results

You are looking at 1 - 10 of 12 items for :

  • "iron dextran" x
Clear All
Full access

Jeffrey A. Gilreath, David D. Stenehjem and George M. Rodgers

History of Total Dose Infusion Parenteral iron administration was introduced approximately 60 years ago. In 1954, high-molecular-weight (HMW) iron dextran (Imferon) became available as an intramuscular injection in which a “total dose” could

Full access

Christopher A. Laman, Scott B. Silverstein and George M. Rodgers

. Hypersensitivity reactions and deaths associated with intravenous iron preparations . Nephrol Dial Transplant 2005 ; 20 : 1443 – 1449 . 6 Eichbaum Q Foran S Dzik S . Is iron gluconate really safer than iron dextran? Blood 2003 ; 101 : 3756 – 3757

Full access

Michael Auerbach and Harold Ballard

Edited by Kerrin G. Robinson

-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial . J Lab Clin Med 1998 ; 131 : 257 – 260 . 13. Auerbach M Witt D Toler W . Clinical use of the total dose intravenous infusion of iron dextran

Full access

Jennifer M. Hinkel, Edward C. Li and Stephen L. Sherman

products available on the market, iron dextran, iron sucrose, and sodium ferric gluconate, are not specifically approved for the oncology context and are associated with various risks. A survey of NCCN pharmacy directors, described in detail later

Full access

Jeffrey A. Gilreath, Daniel S. Sageser, James A. Jorgenson and George M. Rodgers

): S11 – 145 . 33. INFeD [package insert] . Morristown, NJ : Watson Pharmaceuticals, Inc. ; 2001 . 34. Anuradha S Singh NP Agarwal SK . Total dose infusion iron dextran therapy in predialysis chronic renal failure patients

Full access

Jeffrey Crawford and George M. Rodgers

Chemotherapy-Induced Anemia recommends 3 products: low-molecular-weight iron dextran, ferric gluconate, and iron sucrose. The panel does not recommend high-molecular-weight iron dextran (safety reasons) or ferumoxytol (lack of data in patients with cancer

Full access

. III MD 5 2012 10 10 5 5 628 628 653 653 0100628 10.6004/jnccn.2012.0064 Update on Safety of ESAs in Cancer-Induced Anemia Glaspy John MD 5 2012 10 10 5 5 659 659 666 666 jnccn0100659 10.6004/jnccn.2012.0065 Total Dose Iron Dextran

Full access

George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic and Alva B. Weir III

-molecular-weight iron dextran, ferric gluconate, and iron sucrose). 73 Evidence from 5 published studies using iron in conjunction with an ESA suggests that intravenous iron is superior to oral iron. 74 – 78 Patients participating in these trials had serum ferritin

Full access

George M. Rodgers

erythropoietic-stimulating agent use in hematology-oncology patients . J Natl Compr Canc Netw 2008 ; 6 : 577 – 584 . 12 Gilreath JA Stenehjem DD Rodgers GM . Total dose iron dextran infusion in cancer patients: is it saFe2+? J Natl Compr Canc

Full access

Anat Gafter-Gvili, David P. Steensma and Michael Auerbach

-molecular-weight iron dextran (HMW ID), low-molecular-weight (LMW) ID, ferric gluconate, iron sucrose, and 3 newer formulations: ferumoxytol, ferric carboxymaltose, and iron isomaltoside, which features tighter elemental iron binding to novel carbohydrate cores and can